Dilan S. Athauda

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.

Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.

Journal: Brain : a journal of neurology

Published: April 14, 2026

The promise of GLP-1 receptor agonists for neurodegenerative diseases.

The promise of GLP-1 receptor agonists for neurodegenerative diseases.

Journal: The Journal of clinical investigation

Published: February 16, 2026

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Journal: Clinical trials (London, England)

Published: December 01, 2025

Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy-the nucleic acid-linked immuno-sandwich assay.

Peripheral and CSF protein quantification in Parkinson's disease and multiple system atrophy-the nucleic acid-linked immuno-sandwich assay.

Journal: Brain communications

Published: October 08, 2025

Astrocytic RNA editing regulates the host immune response to alpha-synuclein.

Astrocytic RNA editing regulates the host immune response to alpha-synuclein.

Journal: Science advances

Published: April 11, 2025

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.

Journal: Annals of neurology

Published: March 25, 2025

Mapping the distribution of neurotransmitters to resting-state functional connectivity in Parkinson's disease.

Mapping the distribution of neurotransmitters to resting-state functional connectivity in Parkinson's disease.

Journal: Brain communications

Published: March 17, 2025

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 06, 2024

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: October 07, 2024

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Journal: Movement disorders clinical practice

Published: April 10, 2024

The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.

The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.

Journal: Nature biotechnology

Published: August 10, 2023

Commentary: "Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: a systematic review and meta-analysis".

Commentary: "Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: a systematic review and meta-analysis".

Journal: Frontiers in aging neuroscience

Published: May 16, 2023

Showing 1-12 of 53

Last Updated: 09/26/2026